Biophytis SA, a clinical-stage biotechnology company focused on developing therapeutics aimed at slowing the degenerative processes associated with age-related diseases, and Seqens, a global player in solutions and ingredients for the pharmaceutical and specialty markets, reported the conclusion of a master agreement for the production of the active compound in Sarconeos (BIO101), Biophytis’ lead drug candidate developed for three indications: severe forms of Covid-19, sarcopenia and Duche...